UPC Analytics
ENDE
Overview · Filed:

APL_8326/2025

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

AppealsMain AppealCourt of AppealAppeal RoP220.2
  • 2025-04-14Procedural onlyappeal_decisionAppeal RoP220.2

    The Court of Appeal reversed the first-instance order and granted Stadapharm access to the statement of claim and annexes filed by Accord in a now-withdrawn declaration of non-infringement action against Novartis, finding that following withdrawal of the main proceedings all parties consented and no confidentiality concerns remained apart from personal data redactions.